MDGL MADRIGAL PHARMACEUTICALS INC revenue, earnings and financials
For the quarter ended June 30, 2026, MADRIGAL PHARMACEUTICALS INC reported revenue of $364M (up 71.2% from a year earlier), net income of −$57.9M and diluted EPS of −$1.99; over the last four quarters revenue was $1.28B and net income −$325M; for the fiscal year ended December 2025 revenue was $958M, up 432.1% on the year before.
MDGL annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $958M, gross profit n/a, operating income −$300M, net income −$288M (margin -30.1%), EPS −$10.15
- Fiscal year ended Dec 2024: revenue $180M, gross profit n/a, operating income −$498M, net income −$466M (margin -258.6%), EPS −$17.31
- Fiscal year ended Dec 2023: revenue $0, gross profit n/a, operating income −$380M, net income −$374M (margin n/a), EPS −$17.33
- Fiscal year ended Dec 2022: revenue $0, gross profit n/a, operating income −$294M, net income −$295M (margin n/a), EPS −$17.23
- Fiscal year ended Dec 2021: revenue $0, gross profit n/a, operating income −$242M, net income −$242M (margin n/a), EPS −$14.63
MDGL quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $364M (up 71.2% year over year), net income −$57.9M, EPS −$1.99
- Quarter ended Mar 31, 2026: revenue $311M (up 126.8% year over year), net income −$94.4M, EPS −$3.25
- Quarter ended Dec 31, 2025 (from the annual report): revenue $321M (up 210.8% year over year), net income −$58.6M, EPS −$2.03
- Quarter ended Sep 30, 2025: revenue $287M (up 362.0% year over year), net income −$114M, EPS −$4.01
- Quarter ended Jun 30, 2025: revenue $213M (up 1353.8% year over year), net income −$42.3M, EPS −$1.50
- Quarter ended Mar 31, 2025: revenue $137M, net income −$73.2M, EPS −$2.61
- Quarter ended Dec 31, 2024 (from the annual report): revenue $103M, net income −$59.4M, EPS $2.09
- Quarter ended Sep 30, 2024: revenue $62.2M, net income −$107M, EPS −$4.92
- Quarter ended Jun 30, 2024: revenue $14.6M, net income −$152M, EPS −$7.10
- Quarter ended Mar 31, 2024: revenue $0, net income −$148M, EPS −$7.38
- Quarter ended Dec 31, 2023: revenue $0, net income −$112M, EPS −$5.68
- Quarter ended Sep 30, 2023: revenue $0, net income −$98.7M, EPS −$5.34
- Quarter ended Jun 30, 2023: revenue $0, net income −$85.8M, EPS −$4.69
- Quarter ended Mar 31, 2023: revenue $0, net income −$76.9M, EPS −$4.23
- Quarter ended Dec 31, 2022: revenue $0, net income −$85.9M, EPS −$4.98
- Quarter ended Sep 30, 2022: revenue $0, net income −$81.2M, EPS −$4.75
- Quarter ended Jun 30, 2022: revenue $0, net income −$70.7M, EPS −$4.14
- Quarter ended Mar 31, 2022: revenue $0, net income −$57.5M, EPS −$3.36
- Quarter ended Dec 31, 2021 (from the annual report): revenue $0, net income −$64.5M, EPS −$3.78
- Quarter ended Sep 30, 2021: revenue $0, net income −$63.1M, EPS −$3.79
MDGL cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$190M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$456M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$324M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$225M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$184M, share buybacks n/a
MDGL balance sheet
- Jun 30, 2026: cash $293M, total assets $1.24B, total liabilities $721M, shareholders' equity $524M, long-term debt $341M
- Mar 31, 2026: cash $227M, total assets $1.23B, total liabilities $684M, shareholders' equity $543M, long-term debt $340M
- Dec 31, 2025: cash $199M, total assets $1.26B, total liabilities $657M, shareholders' equity $603M, long-term debt $340M
- Sep 30, 2025: cash $296M, total assets $1.36B, total liabilities $737M, shareholders' equity $626M, long-term debt $340M
- Jun 30, 2025: cash $186M, total assets $1.02B, total liabilities $319M, shareholders' equity $696M, long-term debt $118M
- Mar 31, 2025: cash $184M, total assets $997M, total liabilities $286M, shareholders' equity $711M, long-term debt $118M
- Dec 31, 2024: cash $100M, total assets $1.04B, total liabilities $288M, shareholders' equity $754M, long-term debt $118M
- Sep 30, 2024: cash $233M, total assets $1.07B, total liabilities $296M, shareholders' equity $777M, long-term debt $117M
What is MDGL's revenue?
MADRIGAL PHARMACEUTICALS INC reported $1.28B of revenue over its last four quarters, through June 30, 2026.
Is MDGL profitable?
No. MADRIGAL PHARMACEUTICALS INC lost $325M over the last four quarters.
What is MDGL's EPS?
Diluted earnings per share over the last four quarters were −$11.28; −$1.99 in the latest quarter.